COVID-19肺炎微创尸检30例中进展为纤维化性弥漫性肺泡损伤
基于2020年2–3月武汉30例COVID-19微创尸检,平均年龄69岁,病程16–82天。28例(93.3%)见弥漫性肺泡损伤,其中急性32%、机化25%、纤维化43%。纤维化性DAD患者较急性DAD年轻约10岁且病程、住院和机械通气时间更长。
要点
- COVID-19肺炎DAD可进展至纤维化期,尸检中纤维化型占43%。
- 纤维化性DAD与更长病程、住院及机械通气时间相关。
- 存活者是否遗留肺纤维化及发生率需临床影像随访。
核心结论
- COVID-19肺炎患者发生DAD后可进展为纤维化型。
- 纤维化性DAD见于致死病例,存活者肺纤维化风险及频率待随访研究。
研究设计与样本
- 对2020年2–3月武汉30例COVID-19感染尸检病例进行详细组织病理学研究,采用微创尸检。
- 平均年龄69岁,男性20例(67%)、女性10例(33%),70.0%有基础合并症。
- 病程16–82天(中位数42天)。
主要发现
- 28例(93.3%)见弥漫性肺泡损伤(DAD),以急性(32%)、机化(25%)和/或纤维化(43%)模式为主。
- 纤维化性DAD患者较急性DAD年轻约10岁(P=0.034),病程(P=0.033)、住院(P=0.037)和机械通气(P=0.014)时间更长。
- 机化性DAD患者较急性DAD病程(P=0.032)和住院(P=0.023)时间更长。
临床怎么用
- 病理诊断COVID-19肺炎DAD时需注意识别机化及纤维化模式。
- 对病程较长、住院或机械通气时间长的患者应警惕纤维化性DAD。
局限性
- 基于30例微创尸检的观察性研究,样本量有限。
- 存活者肺纤维化风险及发生率需进一步临床和影像随访研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), infection has been deemed as a global pandemic by the World Health Organisation. While diffuse alveolar damage (DAD) is recognised to be the primary manifestation of COVID-19 pneumonia, there has been little emphasis on the progression to the fibrosing phase of DAD. This topic is of great interest, due to growing concerns regarding the potential long-term complications in prolonged survivors. METHODS AND RESULTS: Here we report a detailed histopathological study of 30 autopsy cases with COVID-19 virus infection, based on minimally invasive autopsies performed between February and March, 2020. The mean age was 69 years, with 20 (67%) males and 10 (33%) females and frequent (70.0%) underlying comorbidities. The duration of illness ranged from 16 to 82 (median = 42) days. Histologically, the most common manifestation was diffuse alveolar damage (DAD) in 28 (93.3%) cases which showed predominantly acute (32%), organising (25%) and/or fibrosing (43%) patterns. Patients with fibrosing DAD were one decade younger (P = 0.034) and they had a longer duration of illness (P = 0.033), hospitalisation (P = 0.037) and mechanical ventilation (P = 0.014) compared to those with acute DAD. Patients with organising DAD had a longer duration of illness (P = 0.032) and hospitalisation (P = 0.023) compared to those with acute DAD. CONCLUSIONS: COVID-19 pneumonia patients who develop DAD can progress to the fibrosing pattern. While we observed fibrosing DAD in fatal cases, whether or not surviving patients are at risk for developing pulmonary fibrosis and the frequency of this complication will require further clinical and radiological follow-up studies.
引用
- Li Y, Wu J, Wang S, et al. Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China. Histopathology. 2020. PMID: 32926596. doi:10.1111/his.14249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。